People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a ...

The likelihood for antibody-mediated rejection in lung transplant recipients was heightened with vs. without GLP-1 receptor ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

There is a low incidence rate of suicide-related adverse events among adults with diabetes or obesity being treated with GLP-1 RAs.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes and sometimes obesity. GLP-1 RAs are very effective at lowering blood sugar levels.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

New research highlights how GLP-1 receptor agonists influence gut bacteria, offering insights into their broader metabolic and anti-inflammatory benefits. Study: Effects of GLP-1 Analogues and ...

The researchers found that while most glucose-lowering therapies were not significantly associated with a reduction in dementia risk, one class of drugs—known as GLP-1 receptor agonists (GLP ...